paroxetine has been researched along with Phobic Disorders in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (25.81) | 18.2507 |
| 2000's | 35 (56.45) | 29.6817 |
| 2010's | 11 (17.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orlando, JM | 1 |
| Bernstein, GA; Book, SW; Kushner, MG; Miller, PM; Randall, CL; Randall, PK; Smith, JP; Specker, SM; Thomas, SE | 1 |
| Bani, M; Deus, J; Farré, M; Fernandes, S; Fina, P; Giménez, M; López-Solà, M; Martín-Santos, R; Merlo-Pich, E; Ortiz, H; Pujol, J; Soriano-Mas, C; Zancan, S | 1 |
| Davis, ML; Hofmann, SG; Smits, JA | 1 |
| Hirsch, J; Pantazatos, SP; Schneier, F; Talati, A | 1 |
| Blanco, C; Cohen, JN; Drabick, DA; Heimberg, RG; Liebowitz, MR; Potter, CM; Schneier, FR | 1 |
| Nagata, T; Nakajima, T; Teo, AR; van Vliet, I; Yamada, H; Yoshimura, C | 1 |
| Hirsch, J; Pomplun, M; Schneier, FR; Sy, M | 1 |
| Barros, RE | 1 |
| Neumann, ID; Slattery, DA; Toth, I | 1 |
| Blanco, C; Gorenstein, LA; Heimberg, RG; Liebowitz, MR; Schneier, FR | 1 |
| Abi-Dargham, A; Coplan, JD; Gorman, JM; Huang, Y; Hwang, DR; Kent, JM; Laruelle, M; Lombardo, I; Mawlawi, O; Slifstein, M; Van Heertum, RL | 1 |
| Hair, T; Kumar, R; Stein, DJ; Versiani, M | 1 |
| Beck, N; Warnke, A | 1 |
| Stein, MB | 1 |
| Wagner, KD | 1 |
| Kobayashi, N; Kurauchi, S; Nomura, S; Sano, SY; Sawamura, T; Shigemura, J | 1 |
| Heinz, A; Ströhle, A; Trendelenburg, G | 1 |
| Bergtholdt, B; Davy, KL; Lepola, U; Ruggiero, L; St Lambert, J | 1 |
| Seedat, S; Stein, MB | 1 |
| Amering, M; Bankier, B; Berger, P; Holzinger, A; Katschnig, H; Sachs, G | 1 |
| Allgulander, C; Dahl, AA; Emilien, G; Lepola, U; Mangano, R; Sjödin, I; Zhang, J | 1 |
| Brooks, SJ; Kutcher, S | 1 |
| Fontanella, BJ | 1 |
| Berard, R; Carpenter, DJ; Davy, K; Gee, M; Machin, A; Perera, P; Stein, MB; Wagner, KD; Wetherhold, E | 1 |
| Ballenger, JC | 1 |
| Gelenberg, AJ; Liebowitz, MR; Munjack, D | 1 |
| Malik, A; Ravasia, S | 1 |
| Bennett, M; Mancini, C; Patterson, B; Van Ameringen, M | 1 |
| Connor, KM; Cook, JL; Davidson, JR | 1 |
| Iketani, T; Kataoka, K; Kiriike, N; Nagata, T; van Vliet, I; Yamada, H | 1 |
| Dervaux, A | 1 |
| Davidson, JR | 1 |
| Book, SW; Randall, CL; Randall, PK; Thomas, SE | 1 |
| Bravo-Mehmedbasić, A; Dzubur-Kulenović, A; Kucukalić, A | 1 |
| Chartier, MJ; Delaney, SM; Hazen, AL; Kroft, CD; Stein, MB | 1 |
| Alpert, JE; Fava, M; Maddocks, A; Rosenbaum, JF | 1 |
| Ringold, AL | 1 |
| Chale, RA; Chartier, MJ; Coté, D; Hazen, AL; Kroft, CD; Stein, MB; Walker, JR | 1 |
| Ameringen, MV; Mancini, C | 1 |
| Bushnell, W; Gergel, I; Liebowitz, MR; Lydiard, RB; Pitts, CD; Stein, MB | 1 |
| Bell, CJ; Malizia, AL; Nutt, DJ | 1 |
| Montgomery, SA | 1 |
| Lydiard, RB | 1 |
| Vallée, JP | 1 |
| Berk, M; Els, C; Emsley, RA; Gittelson, L; Hunter, B; Oakes, R; Stein, DJ; Wilson, D | 1 |
| Liebowitz, MR | 1 |
| Allgulander, C | 1 |
| Farvolden, P; Mancini, C; Oakman, JM; Van Ameringen, M | 1 |
| Baldwin, D; Bobes, J; Faure, M; Scharwächter, I; Stein, DJ | 1 |
| Ben-Zion, IZ; Benjamin, J; Dannon, P; Karbofsky, E | 1 |
| Bobes, J; Lydiard, RB | 1 |
| Baldwin, DS | 1 |
| Schneier, FR | 1 |
| Allgulander, C; Nilsson, B | 1 |
| Chao, J; Hami, S; Sareen, J; Stein, MB | 1 |
| Healy, D | 1 |
| Brady, KT; Davidson, JR; Johnson, MR; Randall, CL; Sonne, SC; Thevos, AK; Thomas, SE; Willard, SL | 1 |
| Hunter, B; Kumar, R; Pitts, CD; Stein, DJ; Stein, MB | 1 |
| Lehman, RB | 1 |
9 review(s) available for paroxetine and Phobic Disorders
| Article | Year |
|---|---|
Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis.
Topics: Antidepressive Agents; Antipsychotic Agents; Cyclohexanols; Humans; Monoamine Oxidase Inhibitors; Paroxetine; Phenelzine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Advances in recognition and treatment of social anxiety disorder: a 10-year retrospective.
Topics: Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Humans; Paroxetine; Phobic Disorders; Psychiatric Status Rating Scales | 2003 |
Remission rates in patients with anxiety disorders treated with paroxetine.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Female; Humans; Longitudinal Studies; Male; Middle Aged; Obsessive-Compulsive Disorder; Panic Disorder; Paroxetine; Phobic Disorders; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Treatment Outcome | 2004 |
An evaluation of paroxetine in generalised social anxiety disorder.
Topics: Anxiety Disorders; Clinical Trials as Topic; Drug Evaluation; Humans; Paroxetine; Phobic Disorders | 2005 |
Pharmacotherapy of social anxiety disorder: what does the evidence tell us?
Topics: Clonazepam; Comorbidity; Drug Therapy, Combination; Humans; Paroxetine; Phobic Disorders; Psychotropic Drugs; Secondary Prevention; Sertraline; Treatment Outcome | 2006 |
Brain mechanisms of social anxiety disorder.
Topics: Animals; Brain; Caffeine; Carbon Dioxide; Cholecystokinin; Dopamine; Fear; Fenfluramine; Humans; Panic Disorder; Paroxetine; Phobic Disorders; Piperazines; Rats; Ritanserin; Selective Serotonin Reuptake Inhibitors; Serotonin; Tomography, Emission-Computed | 1998 |
The role of drug therapy in social phobia.
Topics: Humans; Paroxetine; Phobic Disorders; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1998 |
Update on the diagnosis and treatment of social anxiety disorder.
Topics: Adolescent; Adult; Anxiety Disorders; Cognitive Behavioral Therapy; Comorbidity; Diagnosis, Differential; Female; Humans; Male; Mental Disorders; Mood Disorders; Paroxetine; Phobic Disorders; Quality of Life; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Treatment of social phobia with antidepressants.
Topics: Antidepressive Agents; Controlled Clinical Trials as Topic; Drug Approval; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Paroxetine; Phenelzine; Phobic Disorders; Piperidines; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; United States | 2001 |
31 trial(s) available for paroxetine and Phobic Disorders
| Article | Year |
|---|---|
Treating individuals with social anxiety disorder and at-risk drinking: phasing in a brief alcohol intervention following paroxetine.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Antidepressive Agents, Second-Generation; Anxiety; Anxiety Disorders; Combined Modality Therapy; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Paroxetine; Phobic Disorders; Social Behavior Disorders | 2013 |
Functional effects of chronic paroxetine versus placebo on the fear, stress and anxiety brain circuit in Social Anxiety Disorder: initial validation of an imaging protocol for drug discovery.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety; Brain; Brain Mapping; Fear; Female; Humans; Image Processing, Computer-Assisted; Male; Motor Activity; Paroxetine; Phobic Disorders; Speech; Stress, Psychological; Time Factors; Visual Analog Scale; Visual Perception; Young Adult | 2014 |
Neural response to eye contact and paroxetine treatment in generalized social anxiety disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Brain; Brain Mapping; Eye Movements; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Oxygen; Paroxetine; Phobic Disorders; Photic Stimulation; Young Adult | 2011 |
Social anxiety and functional impairment in patients seeking surgical evaluation for hyperhidrosis.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; Cooperative Behavior; Disability Evaluation; Female; Humans; Hyperhidrosis; Interdisciplinary Communication; Male; Middle Aged; Paroxetine; Patient Care Team; Phobic Disorders; Psychophysiologic Disorders; Social Adjustment | 2012 |
Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Personality Assessment; Phobic Disorders; Recurrence; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2002 |
Controlled-release paroxetine in the treatment of patients with social anxiety disorder.
Topics: Adult; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Paroxetine; Personality Assessment; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder.
Topics: Adult; Ambulatory Care; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Female; Humans; Male; Panic Disorder; Paroxetine; Personality Disorders; Phobic Disorders; Prognosis; Proportional Hazards Models; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Control Groups; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Phobic Disorders; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
The Kutcher Generalized Social Anxiety Disorder Scale for Adolescents: assessment of its evaluative properties over the course of a 16-week pediatric psychopharmacotherapy trial.
Topics: Adolescent; Aging; Antidepressive Agents, Second-Generation; Anxiety; Child; Depressive Disorder; Double-Blind Method; Female; Humans; Interpersonal Relations; Male; Paroxetine; Phobic Disorders; Psychiatric Status Rating Scales; Psychometrics; Reproducibility of Results; Sex Characteristics; Treatment Outcome | 2004 |
A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder.
Topics: Adolescent; Age Factors; Ambulatory Care; Child; Double-Blind Method; Drug Administration Schedule; Feeding and Eating Disorders; Female; Humans; Male; Paroxetine; Personality Inventory; Phobic Disorders; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Vomiting | 2004 |
Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Nausea; Paroxetine; Phobic Disorders; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial.
Topics: Botulinum Toxins, Type A; Comorbidity; Double-Blind Method; Humans; Hyperhidrosis; Injections, Intradermal; Neurotoxins; Paroxetine; Phobic Disorders; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2006 |
An open trial of paroxetine for the "offensive subtype" of taijin kyofusho and social anxiety disorder.
Topics: Adult; Awareness; Cultural Characteristics; Delusions; Fear; Female; Humans; Interpersonal Relations; Male; Middle Aged; Paroxetine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Treatment Outcome; Trust | 2006 |
Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder.
Topics: Adult; Alcohol-Related Disorders; Comorbidity; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Paroxetine; Phobic Disorders; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2008 |
Paroxetine in the treatment of post traumatic stress disorder: our experiences.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Dose-Response Relationship, Drug; Health Surveys; Humans; Outcome Assessment, Health Care; Paranoid Disorders; Paroxetine; Phobic Disorders; Stress Disorders, Post-Traumatic; Treatment Outcome | 2008 |
Childhood psychopathology retrospectively assessed among adults with early onset major depression.
Topics: 1-Naphthylamine; Adolescent; Adult; Anxiety Disorders; Child; Child Behavior Disorders; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Imipramine; Male; Mental Disorders; Middle Aged; Paroxetine; Personality Development; Phobic Disorders; Recurrence; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 1994 |
Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.
Topics: Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Humans; Male; Paroxetine; Phobic Disorders; Time Factors | 1996 |
Paroxetine in social phobia.
Topics: Adolescent; Adult; Aged; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Phobic Disorders; Pilot Projects; Psychiatric Status Rating Scales; Treatment Outcome | 1996 |
Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Humans; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Paroxetine; Personality Tests; Phobic Disorders; Selective Serotonin Reuptake Inhibitors | 1998 |
Implications of the severity of social phobia.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Paroxetine; Personality Inventory; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1998 |
[Generalized social phobias, are they sufficiently recognised and treated?].
Topics: Female; Humans; Male; Paroxetine; Phobic Disorders; Placebos | 1999 |
A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Double-Blind Method; Humans; Middle Aged; Paroxetine; Phobic Disorders; Placebos; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Paroxetine in social anxiety disorder: a randomized placebo-controlled study.
Topics: Adult; Female; Humans; Male; Paroxetine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Treatment Outcome | 1999 |
Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Double-Blind Method; Female; Humans; Interpersonal Relations; Male; Middle Aged; Paroxetine; Phobic Disorders; Treatment Outcome | 1999 |
Double-blind placebo-controlled pilot study of paroxetine for specific phobia.
Topics: Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Phobic Disorders; Pilot Projects | 2000 |
Clinical experience with paroxetine in social anxiety disorder.
Topics: Humans; Paroxetine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2000 |
A prospective study of 86 new patients with social anxiety disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Female; Humans; Male; Middle Aged; Paroxetine; Patient Compliance; Phobic Disorders; Prognosis; Prospective Studies; Treatment Outcome | 2001 |
Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study.
Topics: Cross-Over Studies; Double-Blind Method; Humans; Paroxetine; Phobic Disorders; Pindolol; Placebos; Treatment Outcome | 2001 |
Paroxetine for social anxiety and alcohol use in dual-diagnosed patients.
Topics: Adolescent; Adult; Aged; Alcoholism; Comorbidity; Diagnosis, Dual (Psychiatry); Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Phobic Disorders; Pilot Projects; Treatment Outcome | 2001 |
Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials.
Topics: Drug Administration Schedule; Female; Humans; Logistic Models; Male; Paroxetine; Phobic Disorders; Probability; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome | 2002 |
22 other study(ies) available for paroxetine and Phobic Disorders
| Article | Year |
|---|---|
Animal Behavior Case of the Month.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Behavior, Animal; Diazepam; Dog Diseases; Dogs; Fear; Fluoxetine; Gabapentin; Male; Noise; Paroxetine; Phobic Disorders | 2017 |
A pilot study of gray matter volume changes associated with paroxetine treatment and response in social anxiety disorder.
Topics: Adult; Female; Gray Matter; Humans; Magnetic Resonance Imaging; Male; Paroxetine; Phobic Disorders; Pilot Projects; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2015 |
Clinical presentation and pharmacotherapy response in social anxiety disorder: The effect of etiological beliefs.
Topics: Adolescent; Adult; Anxiety; Depression; Emotions; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Middle Aged; Paroxetine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult | 2015 |
Comorbid social withdrawal (hikikomori) in outpatients with social anxiety disorder: clinical characteristics and treatment response in a case series.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclopropanes; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluvoxamine; Humans; Interview, Psychological; Japan; Male; Milnacipran; Obsessive-Compulsive Disorder; Paroxetine; Phobic Disorders; Psychotherapy, Group; Reactive Attachment Disorder; Retrospective Studies; Social Isolation; Treatment Outcome; Young Adult | 2013 |
Paruresis and parcopresis in social phobia: a case report.
Topics: Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; Defecation; Humans; Male; Paroxetine; Phobic Disorders; Urination Disorders; Young Adult | 2011 |
Social fear conditioning: a novel and specific animal model to study social anxiety disorder.
Topics: Animals; Anti-Anxiety Agents; Conditioning, Psychological; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Exploratory Behavior; Extinction, Psychological; Fear; Male; Maze Learning; Mental Recall; Paroxetine; Phobic Disorders; Swimming; Time Factors | 2012 |
Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652.
Topics: Adult; Brain; Brain Mapping; Carrier Proteins; Dose-Response Relationship, Drug; Female; Humans; Image Processing, Computer-Assisted; Isoquinolines; Magnetic Resonance Imaging; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Personality Inventory; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Tomography, Emission-Computed | 2002 |
[Day care treatment of 2 siblings with elective mutism].
Topics: Acculturation; Behavior Therapy; Child; Combined Modality Therapy; Day Care, Medical; Ethnicity; Female; Germany; Humans; Mutism; Paroxetine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Shyness; Siblings; Social Environment; Social Isolation; Thailand | 2003 |
Paroxetine: new indication. In social phobia: minimal assessment.
Topics: Clinical Trials as Topic; Drug Approval; Drug Evaluation; France; Humans; Paroxetine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2003 |
Paroxetine treatment of mood and anxiety disorders in children and adolescents.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Depressive Disorder, Major; Humans; Mood Disorders; Paroxetine; Phobic Disorders | 2003 |
The effect of paroxetine on Taijinkyofusho: a report of three cases.
Topics: Adult; Ambulatory Care; Culture; Female; Humans; Internal-External Control; Japan; Male; Medicine, Traditional; Middle Aged; Paroxetine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Self Concept; Shame; Social Perception | 2003 |
Gamma-hydroxybutyrate dependence with social phobia.
Topics: Adjuvants, Anesthesia; Adult; Cognitive Behavioral Therapy; Humans; Male; Paroxetine; Phobic Disorders; Psychomotor Agitation; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Sodium Oxybate | 2004 |
[Social anxiety and propranolol abuse: a case study].
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Female; Humans; Paroxetine; Phobic Disorders; Propranolol; Self Medication; Substance-Related Disorders | 2003 |
Positional asphyxiation from paroxetine.
Topics: Adult; Asphyxia; Depressive Disorder, Major; Humans; Male; Paroxetine; Phobic Disorders; Poisoning; Posture; Selective Serotonin Reuptake Inhibitors | 2005 |
[Cannabis dependence and social phobia].
Topics: Adult; Cyclohexanols; Drug Therapy, Combination; Humans; Male; Marijuana Abuse; Paroxetine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2005 |
[3H]paroxetine binding to platelets of patients with social phobia: comparison to patients with panic disorder and healthy volunteers.
Topics: Adult; Blood Platelets; Carrier Proteins; Female; Humans; Kinetics; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Panic Disorder; Paroxetine; Phobic Disorders; Radioligand Assay; Reference Values; Serotonin Plasma Membrane Transport Proteins | 1995 |
Paroxetine efficacy in social phobia.
Topics: Adolescent; Female; Humans; Male; Middle Aged; Paroxetine; Phobic Disorders; Treatment Outcome | 1994 |
Serotonergic agents in the treatment of social phobia in children and adolescents: a case series.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Female; Humans; Male; Paroxetine; Phobic Disorders; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Triazoles | 1999 |
Therapeutic advances: paroxetine for the treatment of social anxiety disorder.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Paroxetine; Personality Inventory; Phobic Disorders; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2000 |
[Generalized social anxiety disorders: recognized too rarely].
Topics: Anxiety Disorders; Humans; Paroxetine; Phobic Disorders; Randomized Controlled Trials as Topic; Treatment Outcome | 1999 |
Have drug companies hyped social anxiety disorder to increase sales. Yes: marketing hinders discovery of long-term solutions.
Topics: Drug Industry; Humans; Paroxetine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors | 2001 |
Rapid resolution of social anxiety disorder, selective mutism, and separation anxiety with paroxetine in an 8-year-old girl.
Topics: Anxiety, Separation; Child; Female; Humans; Mutism; Paroxetine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2002 |